Strides Arcolab has slipped by 4% at Rs 865 in an otherwise firm market after the pharmaceutical company said has received a warning letter from the United States Food and Drug Administration (US FDA) for its sterile manufacturing facility at Bangalore.
The sterile manufacturing facility 2 at Bangalore of Agila Specialties Private Limited, a wholly owned subsidiary of the company, has received a warning letter from the USFDA, Strides Arcolab said in a regulatory filing.
The company is committed to work collaboratively and expeditiously with the USFDA to resolve concerns cited in the warning letter in the shortest possible time, it added.
Meanwhile, the company said its oncology facility at Bangalore of Agila Specialties Private Limited was also inspected recently by the USFDA and this facility has cleared the inspection with "Zero 483 status".
The company has 8 USFDA approved sterile manufacturing facilities.
The stock opened at Rs 902 and hit a low of Rs 840 on NSE. A combined 323,379 shares change hands on the counter so far on NSE and BSE.
The sterile manufacturing facility 2 at Bangalore of Agila Specialties Private Limited, a wholly owned subsidiary of the company, has received a warning letter from the USFDA, Strides Arcolab said in a regulatory filing.
The company is committed to work collaboratively and expeditiously with the USFDA to resolve concerns cited in the warning letter in the shortest possible time, it added.
Meanwhile, the company said its oncology facility at Bangalore of Agila Specialties Private Limited was also inspected recently by the USFDA and this facility has cleared the inspection with "Zero 483 status".
The company has 8 USFDA approved sterile manufacturing facilities.
The stock opened at Rs 902 and hit a low of Rs 840 on NSE. A combined 323,379 shares change hands on the counter so far on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%